N4 Pharma Plc
N4P.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | £626 | £1,027 | £1,920 | £1,784 |
| Short-Term Investments | £0 | £0 | £0 | £0 |
| Receivables | £135 | £176 | £210 | £551 |
| Inventory | £0 | £0 | £0 | £0 |
| Other Curr. Assets | £15 | £11 | £37 | £7 |
| Total Curr. Assets | £776 | £1,214 | £2,166 | £2,342 |
| Property Plant & Equip (Net) | £0 | £0 | £0 | £0 |
| Goodwill | £0 | £61 | £0 | £0 |
| Intangibles | £0 | £0 | £0 | £0 |
| Long-Term Investments | £0 | £0 | £0 | £0 |
| Tax Assets | £0 | £0 | £0 | £0 |
| Other NC Assets | £0 | £0 | £0 | £0 |
| Total NC Assets | £0 | £61 | £0 | £0 |
| Other Assets | £0 | £0 | £0 | £0 |
| Total Assets | £776 | £1,275 | £2,166 | £2,342 |
| Liabilities | – | – | – | – |
| Payables | £23 | £20 | £36 | £180 |
| Short-Term Debt | £0 | £0 | £0 | £0 |
| Tax Payable | £0 | £0 | £0 | £0 |
| Deferred Revenue | £0 | £0 | £0 | £0 |
| Other Curr. Liab. | £101 | £68 | £42 | £32 |
| Total Curr. Liab. | £124 | £82 | £78 | £213 |
| LT Debt | £0 | £0 | £0 | £0 |
| Deferred Rev, NC | £0 | £0 | £0 | £0 |
| Deferred Tax Liab, NC | £0 | £0 | £0 | £0 |
| Other NC Liab. | £0 | £0 | £0 | £0 |
| Total NC Liab. | £0 | £0 | £36 | £180 |
| Other Liabilities | £0 | £0 | -£36 | -£180 |
| Cap. Leases | £0 | £0 | £0 | £0 |
| Total Liabilities | £124 | £82 | £78 | £213 |
| Equity | – | – | – | – |
| Pref Stock | £0 | £0 | £0 | £0 |
| Common Stock | £1,579 | £9,346 | £9,206 | £8,995 |
| Retained Earnings | -£10,399 | -£9,341 | -£21,920 | -£20,891 |
| AOCI | £115 | £107 | £104 | £80 |
| Other Equity | £9,468 | £1,016 | £14,699 | £13,946 |
| Total Equity | £648 | £1,128 | £2,088 | £2,130 |
| Supplemental Information | – | – | – | – |
| Minority Interest | £4 | £66 | £0 | £0 |
| Total Liab. & Tot. Equity | £776 | £1,275 | £2,166 | £2,342 |
| Net Debt | -£626 | -£1,027 | -£1,920 | -£1,784 |